PTC have today announced that the Office of New Drugs of the U.S. Food and Drug Administration has reiterated the FDA's prior …
PTC receives formal dispute resolution request decision from the FDARead More

20 February 2018 by abzali123
PTC have today announced that the Office of New Drugs of the U.S. Food and Drug Administration has reiterated the FDA's prior …
PTC receives formal dispute resolution request decision from the FDARead More

16 February 2018 by abzali123
We are happy to share the news that the U.S. Food and Drug Administration (FDA) have published a guidance document for industry, which details what …
FDA share guidance for Duchenne and Becker muscular dystrophy drug developmentRead More

14 February 2018 by abzali123
Download the FAQ Bringing you the most up to date news from the international Duchenne community is one of our core aims. Action Duchenne and …

13 February 2018 by abzali123
Catabasis have reported new positive efficacy and safety results showing preservation of muscle function and sustained condition-modifying effects in …

6 February 2018 by abzali123
Capricor have announced that the U.S. Food and Drug Administration (FDA) has granted CAP-1002 the Regenerative Medicine Advanced Therapy (RMAT) …
Capricor receives FDA RMAT designation for CAP-1002Read More

6 February 2018 by abzali123
Santhera announces the launch of a U.S. Expanded Access Program (EAP) referred to as BreatheDMD with idebenone for patients with DMD. Through the …
Investigational idebenone becomes available through EAP in USRead More

2 February 2018 by abzali123
This study underlines the importance of data collection via patient registries and the critical role of multicenter collaboration in the rare disease …
TREAT-NMD steroids analysis demonstrates the power of ‘real-world’ Registry dataRead More

30 January 2018 by abzali123
Action Duchenne is delighted to hear the continued commitment by NHS England to improve care of those living with rare diseases. This coincides nicely …
Implementation plans for the UK Strategy for Rare DiseasesRead More

26 January 2018 by abzali123
We are delighted to announce that the revised Standards of Care for Duchenne were published in The Lancet Neurology this week; a high-impact …
Revised Standards of Care for Duchenne muscular dystrophyRead More

26 January 2018 by abzali123
On 14 September 2017, the CHMP of the European Medicines Agency (EMA) adopted a negative opinion, recommending the refusal of a change to the …
Santhera Receives Negative CHMP Opinion on Appeal for Authorization of Raxone® in DuchenneRead More

25 January 2018 by abzali123
Diagnosis and management of Duchenne muscular dystrophy Part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and …
Breaking news – updated Standards of Care publishedRead More

25 January 2018 by abzali123
Increase in utrophin protein expression observed Summit accelerating preparations for pivotal clinical trial Ezutromid is a potential …
Positive data from Summit’s PhaseOUT DMD ezutromid clinical trialRead More
Action Duchenne
2nd Floor
South
One Castle Park
Tower Hill
Bristol
BS2 OJA
0300 102 1762
info@actionduchenne.org
